The Food and Drug Administration today revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, FDA said that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. For more details, see the FDA news release.

Related News Articles

Blog
Understanding potential costs is an important part of the patient experience when planning for care, and hospitals and health systems are committed to helping…
Headline
The Centers for Disease Control and Prevention yesterday updated its guidance to help clinicians evaluate and test patients with relevant history, signs and…
Headline
An initial 10 million doses of COVID-19 vaccine are available for children under age 5 if the Food and Drug Administration authorizes and the Centers for…
Headline
AHA Friday urged lawmakers to consider certain changes to the Verifying Accurate Leading-Edge IVCT Development (VALID) Act, legislation that would modify the…
Headline
The Department of Health and Human Services today withdrew a Trump Administration rule that would require the agency to assess periodically each…
Headline
Testifying today at an Occupational Safety and Health Administration hearing, AHA policy staff urged the agency not to finalize its emergency temporary…